ArticleNeuro-oncology2023
Proton therapy for adult craniopharyngioma: Experience of a single institution in 91 consecutive patients.
Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 5 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Impact of patient education and care on quality of life and mental well-being in cancer patients undergoing radiotherapy: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Efficacy and safety of proton therapy and photon therapy for patients with craniopharyngioma: a systematic review and meta‑analysis.Pituitary · 2025Pooled it
- Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm.Endocrine · 2025Pooled it
- The spectrum of radiation therapy options for craniopharyngioma: a systematic review.Journal of neuro-oncology · 2025Pooled it
- Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis.Radiation oncology (London, England) · 2024Pooled it
- BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.The New England journal of medicine · 2023Trial
- Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Journal of neuro-oncology · 2026Article
- Combined surgery and proton radiotherapy in the management of craniopharyngiomas: an update with paradigmatic and challenging case scenarios.Neurosurgical review · 2026Article
- MRI features of craniopharyngiomas in different age groups and pathological subtypes.Frontiers in oncology · 2026Article
- A case-based review of adult-onset craniopharyngioma.Frontiers in endocrinology · 2025Review
- Decision-Making in Clival Mass Lesions: Risk Factors for Malignant Disease and an Illustrative Case Example.Journal of neurological surgery reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCraniopharyngioma (CP) in adults is a rare benign tumor associated with many morbidities, with limited contemporary studies to define treatment, and follow-up guidelines.
methodsA single-center retrospective study was conducted on patients aged ≥ 18 years from 2006-2018 with CP and who were treated with proton therapy (PT). Late toxicity was defined as a minimum of 18 months from diagnosis. Overall survival (OS), local recurrence-free survival (LRFS), and toxicity were characterized using Kaplan-Meier and Cox regression analyses.
resultsNinety-one patients met the criteria, with a median age of 37 years (range 18-82 years). PT was conducted after tumor resection in 88 patients (97%), in 64 patients (70.3%) as an adjuvant strategy and in 27 (29.7%) after recurrent disease. Three patients received exclusive PT. A median MRI follow-up of 39 months revealed 35.2% complete response, 49.5% partial response, and 9.9% stable disease. Five patients developed local recurrence (LR). The pattern of failure study showed that these five LR were within the GTV volume. The 5-year LRFS was 92.0% [CI 95% 84.90-99.60]. All the patients were alive at the end of the follow-up. Patients requiring treatment adaptation during PT tend to have a higher risk of LR (P = .084). Endocrinopathy was the most frequent grade ≥ 2 late toxicity. Among patients who were symptom-free before the start of treatment, none developed hearing toxicity but four (9.8%) developed visual disorders and 10 (11.3%) symptomatic memory impairment. Patients with large tumors had a higher risk of developing symptomatic memory impairment (P = .029).
conclusionAdults with CP treated with PT have favorable survival outcomes, with acceptable late toxicity. Prospective quality-of-life and neurocognitive studies are needed to define late adverse effects better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.